Evaluation of osimertinib efficacy according to body surface area and body mass index in patients with non‐small cell lung cancer harboring an EGFR mutation: A prospective observational study

BACKGROUND: Osimertinib is recommended for non‐small cell lung cancer (NSCLC) patients with EGFR mutation; however, it is unclear whether body size variables affect the efficacy of osimertinib in such patients. This study assessed the potential effect of body surface area (BSA) and body mass index (...

Descripción completa

Detalles Bibliográficos
Autores principales: Ono, Taihei, Igawa, Satoshi, Ozawa, Takahiro, Kasajima, Masashi, Ishihara, Mikiko, Hiyoshi, Yasuhiro, Kusuhara, Seiichiro, Nishinarita, Noriko, Fukui, Tomoya, Kubota, Masaru, Sasaki, Jiichiro, Hisashi, Mitsufuji, Katagiri, Masato, Naoki, Katsuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590234/
https://www.ncbi.nlm.nih.gov/pubmed/30821083
http://dx.doi.org/10.1111/1759-7714.13018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590234/
https://www.ncbi.nlm.nih.gov/pubmed/30821083
http://dx.doi.org/10.1111/1759-7714.13018

Ejemplares similares